Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Stanulla

Showing results (91-100 of 146) with videos related to

Pageof 15
Sort By:
Blood|January 1, 2010
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhoodRashmi B Prasad, Fay J Hosking, Jayaram Vijayakrishnan, et al.
Cancer Cell|November 19, 2019
The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 VulnerabilityYun Huang, Brice Mouttet, Hans-Jörg Warnatz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemiaKjeld Schmiegelow, Mette Frandsen Levinsen, Andishe Attarbaschi, et al.
Blood|April 22, 2015
Central nervous system acute lymphoblastic leukemia: role of natural killer cellsLiron Frishman-Levy, Avishai Shemesh, Allan Bar-Sinai, et al.
Blood Advances|July 12, 2022
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosisFotini Vogiatzi, Julia Heymann, Kristina Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
Cancers|January 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European RegistryBertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Nature Communications|February 13, 2016
A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiologyEric A Hungate, Sapana R Vora, Eric R Gamazon, et al.
Cancers|March 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124Bertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Hemasphere|June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic LeukemiaChiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Pageof 15

Showing results (91-100 of 146) with videos related to

Sort By:
Pageof 15
Blood|January 1, 2010
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhoodRashmi B Prasad, Fay J Hosking, Jayaram Vijayakrishnan, et al.
Cancer Cell|November 19, 2019
The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 VulnerabilityYun Huang, Brice Mouttet, Hans-Jörg Warnatz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemiaKjeld Schmiegelow, Mette Frandsen Levinsen, Andishe Attarbaschi, et al.
Blood|April 22, 2015
Central nervous system acute lymphoblastic leukemia: role of natural killer cellsLiron Frishman-Levy, Avishai Shemesh, Allan Bar-Sinai, et al.
Blood Advances|July 12, 2022
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosisFotini Vogiatzi, Julia Heymann, Kristina Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
Cancers|January 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European RegistryBertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Nature Communications|February 13, 2016
A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiologyEric A Hungate, Sapana R Vora, Eric R Gamazon, et al.
Cancers|March 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124Bertrand Pourroy, Maria D Aumente, Christian Koenecke, et al.
Hemasphere|June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic LeukemiaChiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Pageof 15